Lasa Supergeneri

Why is Lasa Supergenerics Ltd falling/rising?

As of 11-Aug, Lasa Supergenerics Ltd's stock price is at 7.69, reflecting a decline of 1.91%. Despite a recent weekly gain, the stock has significantly underperformed over the year and long-term, with a notable drop of 88.72% over five years.

As of 11-Aug, Lasa Supergenerics Ltd's stock price is falling, currently at 7.69, which reflects a decrease of 0.15 or 1.91%. The stock has been underperforming, having lost 2.04% over the last two days and has experienced consecutive declines. Additionally, it has underperformed its sector by 2.74% today. <BR><BR>Despite a positive performance over the past week with a gain of 9.70%, the year-to-date performance shows a significant decline of 17.93%, and the stock has fallen 27.32% over the past year. The long-term outlook is also concerning, with a staggering drop of 68.94% over three years and 88.72% over five years, while the benchmark Sensex has shown positive returns in the same periods.<BR><BR>While there has been a rise in investor participation, indicated by a 37.46% increase in delivery volume on 10 August compared to the five-day average, the overall trend remains negative. The stock's current price is higher than its short-term moving averages but lower than its 200-day moving average, suggesting a lack of sustained upward momentum.

Which are the latest news on Lasa Supergeneri?

When is the next results date for Lasa Supergenerics Ltd?

Lasa Supergenerics Ltd will announce its results on 14 August 2026.

Lasa Supergenerics Ltd is scheduled to declare its results on 14 August 2026.

What does Lasa Supergeneri do?

Lasa Supergenerics Ltd is a micro-cap company focused on manufacturing and trading pharmaceuticals and biotechnology products. As of March 2026, it reported net sales of 0 Cr and a net profit of -4 Cr, with a market cap of INR 40 Cr.

Overview: <BR>Lasa Supergenerics Ltd is a micro-cap company engaged in the manufacturing and trading of pharmaceuticals, biotechnology products, and chemicals within the Pharmaceuticals & Biotechnology industry.<BR><BR>History: <BR>Lasa Supergenerics Limited was incorporated on March 11, 2016. The latest quarterly results reported net sales and net profit for the period ending March 2026.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 0 Cr (Quarterly Results - Mar 2026) <BR>Most recent Net Profit: -4 Cr (Quarterly Results - Mar 2026) <BR>Market-cap value: INR 40 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: N/A <BR>Industry P/E: 34 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.02 <BR>Return on Equity: -15.59% <BR>Price to Book: 0.46<BR><BR>Contact Details: <BR>Address: C-105 MIDC, Mahad Raigad Maharashtra : 402301 <BR>Tel: 91-2145-232101/232202 <BR>Email: cs@lasalabs.com <BR>Website: http://www.lasalabs.com

How big is Lasa Supergeneri?

As of 10th June, Lasa Supergenerics Ltd has a market capitalization of 40.00 Cr and reported Net Sales of 25.14 Cr, with a Net Profit loss of 34.08 Cr over the latest four quarters. Shareholder's Funds were 83.71 Cr and Total Assets were 101.53 Cr as of March 2025.

As of 10th June, Lasa Supergenerics Ltd has a market capitalization of 40.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, Lasa Supergenerics reported Net Sales of 25.14 Cr. However, the company experienced a Net Profit loss of 34.08 Cr during the same period.<BR><BR>The latest annual period for the balance sheet is March 2025, where Shareholder's Funds amounted to 83.71 Cr and Total Assets were valued at 101.53 Cr.

Who are in the management team of Lasa Supergeneri?

The management team of Lasa Supergeneri includes Omkar P Herlekar (Chairman & Managing Director), Shivanand Hedge (Whole-time Director), and several Independent Directors: Hardesh Tolani, Ajay Sukhwani, Ekta Gurnasinghani, and Manali Bhagtani, along with Mitti M Jain (Company Secretary & Compliance Officer).

The management team of Lasa Supergeneri includes the following members:<BR><BR>1. **Omkar P Herlekar** - Chairman & Managing Director<BR>2. **Shivanand Hedge** - Whole-time Director<BR>3. **Hardesh Tolani** - Independent Director<BR>4. **Ajay Sukhwani** - Independent Director<BR>5. **Ekta Gurnasinghani** - Independent Director<BR>6. **Mitti M Jain** - Company Secretary & Compliance Officer<BR>7. **Manali Bhagtani** - Independent Director<BR><BR>If you need more information about any specific member or their roles, feel free to ask!

Who are the peers of the Lasa Supergeneri?

Lasa Supergeneri's peers include Sandu Pharma, Murae Organisor, Roopa Industries, ANG Lifesciences, Medi Caps, Chandra Bhagat, Welcure Drugs, Guj. Terce Labs, and Medicamen Organ. Most peers exhibit below average management risk and negative returns, with Guj. Terce Labs having the highest 1-year return at -35.72% and Murae Organisor the lowest at -83.76%.

Peers: The peers of Lasa Supergeneri are Sandu Pharma., Murae Organisor, Roopa Industries, ANG Lifesciences, Medi Caps, Chandra Bhagat, Welcure Drugs, Guj. Terce Labs., and Medicamen Organ.<BR><BR>Quality Snapshot: Below Average management risk is observed at Sandu Pharma., Murae Organisor, Roopa Industries, ANG Lifesciences, Medi Caps, Chandra Bhagat, Guj. Terce Labs., and Medicamen Organ., while Average management risk is found at Welcure Drugs. Growth is Excellent at Roopa Industries, Good at Murae Organisor, and Below Average at Sandu Pharma., Lasa Supergeneri, ANG Lifesciences, Medi Caps, Chandra Bhagat, Welcure Drugs, Guj. Terce Labs., and Medicamen Organ. Capital Structure is Good at Sandu Pharma. and Medi Caps, Average at Lasa Supergeneri, and Below Average at Murae Organisor, Roopa Industries, ANG Lifesciences, Chandra Bhagat, Welcure Drugs, Guj. Terce Labs., and Medicamen Organ.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Guj. Terce Labs. at -35.72%, while the peer with the lowest is Murae Organisor at -83.76%. Lasa Supergeneri's 1-year return is -44.40%, which is better than Murae Organisor but worse than Guj. Terce Labs. Additionally, several peers, including Roopa Industries, ANG Lifesciences, Medi Caps, Chandra Bhagat, Welcure Drugs, Guj. Terce Labs., and Medicamen Organ., have negative six-month returns.

Should I buy, sell or hold Lasa Supergenerics Ltd?

Are Lasa Supergenerics Ltd latest results good or bad?

Lasa Supergenerics Ltd's latest results are concerning, with a net profit of -₹2.55 crore and a 93.35% decline in revenue year-on-year, indicating severe operational challenges and raising questions about the company's future viability. Investors should exercise caution due to the company's critical financial situation.

Lasa Supergenerics Ltd's latest results are quite concerning and can be classified as bad. In the third quarter of FY26, the company reported a net profit of -₹2.55 crore, which represents a staggering decline of 146.45% year-on-year. Revenue also fell dramatically by 93.35% compared to the same quarter last year, dropping to just ₹2.20 crore, marking the lowest quarterly revenue in recent history.<BR><BR>The operating margin has deteriorated significantly, now at -34.09%, compared to a positive margin of 0.82% in the previous year. This indicates that the company is facing severe operational challenges and is burning cash at an unsustainable rate. The financial performance suggests fundamental issues within the business model, rather than just temporary market fluctuations.<BR><BR>Overall, the results highlight a critical situation for Lasa Supergenerics, with ongoing losses and a lack of operational viability that raises serious questions about the company's future. Investors should approach this situation with caution, as the company is currently in a state of distress.

How has been the historical performance of Lasa Supergeneri?

Lasa Supergeneri has experienced significant fluctuations in financial performance, with net sales declining from a peak of 202.38 Cr in March 2021 to 142.45 Cr by March 2025, and operating profit turning negative in March 2023 before improving slightly to 6.27 Cr in March 2025. The company has also seen a decrease in reserves and earnings per share, with a negative profit before tax of -19.38 Cr in March 2025.

Answer:<BR>The historical performance of Lasa Supergeneri shows significant fluctuations in key financial metrics over the years.<BR><BR>Breakdown:<BR>Lasa Supergeneri's net sales have varied, peaking at 202.38 Cr in March 2021 but declining to 142.45 Cr by March 2025, with a notable drop from 137.13 Cr in March 2022. Total operating income followed a similar trend, reflecting the same values as net sales. Raw material costs increased to 108.10 Cr in March 2025 from 79.28 Cr in March 2024, while total expenditure rose to 136.18 Cr in March 2025, indicating rising operational costs. Operating profit, which was positive at 47.22 Cr in March 2021, turned negative in March 2023 at -6.59 Cr and improved to 6.27 Cr by March 2025. Profit before tax remained negative, reaching -19.38 Cr in March 2025, with profit after tax also negative at -14.76 Cr. The company's equity capital remained stable at 50.10 Cr from March 2023 to March 2025, but reserves have significantly decreased from 107.96 Cr in March 2022 to 33.61 Cr in March 2025. The earnings per share have shown a downward trend, with a loss of -2.95 in March 2025 compared to a profit of 5.6 in March 2021. Cash flow from operating activities was positive at 2.00 Cr in March 2024, but the overall cash position has deteriorated, with closing cash and cash equivalents at 0.00 Cr in March 2024.

Who are the top shareholders of the Lasa Supergeneri?

The top shareholders of Lasa Supergeneri are primarily its promoters, with Omkar Pravin Herlekar holding 53.65% of the shares. Individual investors own 34.08%, and there are currently no mutual funds or foreign institutional investors involved.

The top shareholders of Lasa Supergeneri primarily consist of its promoters. The largest individual shareholder is Omkar Pravin Herlekar, who holds 53.65% of the shares. Additionally, individual investors collectively own 34.08% of the company. There are no mutual funds or foreign institutional investors (FIIs) holding shares in Lasa Supergeneri at this time.

Is Lasa Supergeneri overvalued or undervalued?

As of April 5, 2023, Lasa Supergeneri is considered overvalued with a high PE ratio of 47.70, negative ROCE of -7.08%, and a significant year-to-date return of -48.37%, indicating it is priced for growth despite poor financial performance compared to peers like Aarti Industries.

As of 5 April 2023, Lasa Supergeneri has moved from a grade of does not qualify to risky. The company is currently overvalued based on its high PE ratio of 47.70, which is significantly above the industry average, and a negative ROCE of -7.08%. Additionally, the EV to EBITDA ratio stands at 11.50, indicating a premium valuation relative to its earnings potential.<BR><BR>In comparison to peers, Lasa Supergeneri's PEG ratio of 0.43 suggests that it is priced for growth, yet its financial performance does not support such a valuation. For instance, a peer like Aarti Industries has a PE ratio of 25.00, which highlights the disparity in valuation metrics. Furthermore, the company has underperformed the Sensex significantly, with a year-to-date return of -48.37% compared to the Sensex's 5.60%, reinforcing the notion that Lasa Supergeneri is overvalued in its current state.

What is the technical trend for Lasa Supergeneri?

As of April 25, 2025, Lasa Supergeneri exhibits a strong bearish trend supported by negative MACD, Bollinger Bands, and moving averages across multiple time frames.

As of 25 April 2025, the technical trend for Lasa Supergeneri has changed from mildly bearish to bearish. The current stance is bearish with strong indicators supporting this view. The MACD is bearish on both the weekly and monthly time frames, and the Bollinger Bands also indicate a bearish trend in both time frames. Daily moving averages confirm the bearish sentiment. The KST is bearish on both weekly and monthly charts, while the Dow Theory shows a mildly bearish stance on the weekly and monthly time frames. The OBV reflects a mildly bearish condition as well. Overall, the combination of these indicators suggests a strong bearish outlook for Lasa Supergeneri.

Has Lasa Supergeneri declared dividend?

Lasa Supergenerics Ltd has declared a 2% dividend, amounting to ₹0.20 per share, with an ex-date of September 16, 2022. However, the company has faced significant negative returns across all periods, with total returns ranging from -34.27% to -81.34% over the past five years.

Lasa Supergenerics Ltd has declared a 2% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 2%<BR>- Amount per share: 0.20<BR>- Ex-date: 16 Sep 22<BR><BR>Dividend Yield: 0%<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was -47.32%, with a dividend return of 0%, resulting in a total return of -47.32%.<BR><BR>Over the past year, the price return was -34.27%, with a dividend return of 0%, leading to a total return of -34.27%.<BR><BR>In the last 2 years, the price return was -40.94%, with a dividend return of 0%, resulting in a total return of -40.94%.<BR><BR>For the 3-year period, the price return was -66.99%, with a dividend return of 0.60%, leading to a total return of -66.39%.<BR><BR>In the 4-year period, the price return was -81.34%, with a dividend return of 0.48%, resulting in a total return of -80.86%.<BR><BR>Over the last 5 years, the price return was -67.68%, with a dividend return of 0.87%, leading to a total return of -66.81%.<BR><BR>Overall, Lasa Supergenerics Ltd has declared a dividend, but the company has experienced significant negative returns across all periods, indicating a challenging financial performance despite the dividend declaration.